Most older adults with hereditary angioedema (HAE) have more frequent and severe swelling attacks, and more chronic diseases that combine to have a negative impact on their quality of life, results from a focus group study show. Other age-related difficulties included financial barriers to accessing medication. Despite these challenges,…
News
Pharvaris is now gearing up startup activities with clinical site investigators and staff to launch a Phase 3 trial next year of PHVS416 — an immediate-release capsule formulation of deucrictibant — as an on-demand treatment for hereditary angioedema (HAE). The Switzerland-based clinical-stage company recently met with the U.S. Food…
A 58-year-old woman developed angioedema of the small bowel after three years of taking lisinopril, an angiotensin-converting enzyme (ACE) inhibitor often used for high blood pressure. The woman switched to amlodipine, a different blood pressure-lowering medication, and her signs and symptoms of angioedema resolved rapidly. Her case was…
Treatment with rituximab — approved for certain cancers to reduce the levels of antibody-producing immune cells — is effective to control swelling attacks in people with acquired angioedema, particularly in cases where the disease is linked to an underlying lymphoma, or a blood cancer that develops in the lymphatic…
Even with long-term preventive treatment, many people with hereditary angioedema still sometimes have swelling attacks that require on-demand treatment, a review study finds.
Children with hereditary angioedema (HAE) may have dozens of swelling attacks until they receive a correct diagnosis of the disease, according to a study in a hospital in Turkey, where the median delay was three years. “Awareness of the symptoms of HAE is necessary and correct diagnosis is…
A 3-point score increase is the minimum change on the widely used Angioedema Control Test (AECT) to reflect meaningful improvement in disease control for people with recurrent angioedema, a study showed. The AECT was developed to help patients keep score of disease control over a recall period, but…
The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to Intellia Therapeutics’ NTLA-2002, an experimental gene-editing therapy to prevent swelling attacks in people with hereditary angioedema (HAE). A PRIME designation supports the development of experimental therapies that address unmet medical needs. Eligibility for this status is…
The design of an ongoing Phase 3 clinical trial testing sebetralstat as an on-demand oral treatment for swelling attacks in hereditary angioedema (HAE) was based on feedback from patients and data from a previous Phase 2 trial. The approach was described in the study “Evaluation…
On-demand and preventive treatment with either icatibant injection or C1 inhibitor (C1-INH) concentrates — which are approved for hereditary angioedema (HAE) — also can help people with acquired angioedema keep swelling under control, according to a small study in Germany. People severely affected with acquired angioedema and no “underlying condition…
Recent Posts
- I have mixed feelings about a potential gene-editing therapy for HAE
- Experimental treatment eases chronic itching, hives in clinical trials
- HAE treatment for preventing swelling attacks wins approval in Canada
- Recurring, severe abdominal pain may be sign of angioedema in children
- Discovering the importance of writing down explicit instructions